CN105102479B - 治疗性cd47抗体 - Google Patents

治疗性cd47抗体 Download PDF

Info

Publication number
CN105102479B
CN105102479B CN201380065387.2A CN201380065387A CN105102479B CN 105102479 B CN105102479 B CN 105102479B CN 201380065387 A CN201380065387 A CN 201380065387A CN 105102479 B CN105102479 B CN 105102479B
Authority
CN
China
Prior art keywords
seq
cancer
antigen
binding fragment
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380065387.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105102479A (zh
Inventor
W·A·弗雷泽
P·T·曼宁
G·弗雷
H·W·常
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN105102479A publication Critical patent/CN105102479A/zh
Application granted granted Critical
Publication of CN105102479B publication Critical patent/CN105102479B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201380065387.2A 2012-12-12 2013-12-12 治疗性cd47抗体 Expired - Fee Related CN105102479B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261736301P 2012-12-12 2012-12-12
US61/736,301 2012-12-12
US201361833691P 2013-06-11 2013-06-11
US61/833,691 2013-06-11
PCT/US2013/074766 WO2014093678A2 (en) 2012-12-12 2013-12-12 Therapeutic cd47 antibodies

Publications (2)

Publication Number Publication Date
CN105102479A CN105102479A (zh) 2015-11-25
CN105102479B true CN105102479B (zh) 2019-06-28

Family

ID=50935081

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380065387.2A Expired - Fee Related CN105102479B (zh) 2012-12-12 2013-12-12 治疗性cd47抗体

Country Status (16)

Country Link
US (4) US20140363442A1 (cg-RX-API-DMAC7.html)
EP (1) EP2931751B1 (cg-RX-API-DMAC7.html)
JP (1) JP6572131B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150093770A (cg-RX-API-DMAC7.html)
CN (1) CN105102479B (cg-RX-API-DMAC7.html)
AU (1) AU2013359167B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015013431A2 (cg-RX-API-DMAC7.html)
CA (1) CA2894439A1 (cg-RX-API-DMAC7.html)
ES (1) ES2786083T3 (cg-RX-API-DMAC7.html)
HK (1) HK1216647A1 (cg-RX-API-DMAC7.html)
IL (1) IL239339A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015007446A (cg-RX-API-DMAC7.html)
PH (1) PH12015501318A1 (cg-RX-API-DMAC7.html)
RU (1) RU2015122228A (cg-RX-API-DMAC7.html)
SG (1) SG11201504469XA (cg-RX-API-DMAC7.html)
WO (2) WO2014093678A2 (cg-RX-API-DMAC7.html)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
JP6572131B2 (ja) 2012-12-12 2019-09-04 バスキュロックス インコーポレイテッド 治療用ｃｄ４７抗体
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
SI2931752T1 (sl) 2012-12-17 2019-12-31 Trillium Therapeutics Inc. Zdravljenje bolezenskih celic CD47+ s fuzijami ALFA-FC SIRP
EP3195168B1 (en) * 2014-07-31 2022-09-07 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
US11053314B2 (en) 2014-10-10 2021-07-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting CD47
EP3221358B1 (en) * 2014-11-18 2021-07-21 Janssen Pharmaceutica, N.V. Cd47 antibodies, methods, and uses
IL286403B2 (en) * 2014-12-05 2023-10-01 Regeneron Pharma Non-human animals possess a humanized CLUSTER OF DIFFERENTIATION 47 gene
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CN107921121B (zh) * 2015-03-04 2022-02-08 索伦托药业有限公司 结合cd47的抗体治疗剂
CN104804093A (zh) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
JP7198083B2 (ja) 2015-08-26 2022-12-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７遮断及び免疫同時刺激アゴニストを用いた標的細胞の枯渇亢進
AU2016319126A1 (en) * 2015-09-10 2018-04-19 Affigen, Inc. Sequencing-directed selection of tumor theranostics
JP6885606B2 (ja) 2015-09-18 2021-06-16 アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. 治療用ｃｄ４７抗体
CA2999277A1 (en) 2015-09-21 2017-03-30 Surface Oncology, Inc. Anti-cd47 antibodies and methods of use
MY189819A (en) 2015-11-27 2022-03-10 Cartherics Pty Ltd Genetically modified cells and uses thereof
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
SI3402820T1 (sl) 2016-01-11 2021-04-30 Forty Seven, Inc. Humanizirana, mišja ali himerna monoklonska protitelesa proti-CD47
CA3011429A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
EP3442593A4 (en) * 2016-04-15 2020-01-01 Trillium Therapeutics Inc. STIMULATION OF MACROPHAGES IN THERAPY BY CD47 BLOCKING
CN106084052B (zh) * 2016-06-17 2019-12-27 长春金赛药业股份有限公司 抗cd47单克隆抗体及其应用
US12344669B2 (en) 2016-06-17 2025-07-01 Changchun Genescience Pharmaceutical Co., Ltd. Anti-CD47 monoclonal antibody and use thereof
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
BR112019008010A2 (pt) 2016-10-20 2019-07-09 I Mab anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
US11446315B2 (en) 2016-11-03 2022-09-20 Pf Argentum Ip Holdings Llc Enhancement of CD47 blockade therapy by proteasome inhibitors
TW201819413A (zh) * 2016-11-28 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ４７抗體、其抗原結合片段及其醫藥用途
EP3345924A1 (en) * 2017-01-10 2018-07-11 Universität Duisburg-Essen Use of cd47 antibodies
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11267885B2 (en) 2017-01-26 2022-03-08 Zlip Holding Limited CD47 antigen binding unit and uses thereof
MX2019011624A (es) * 2017-03-27 2019-12-05 Celgene Corp Metodos y composiciones para la reduccion de la inmunogenicidad.
CA3057718A1 (en) * 2017-03-28 2018-10-04 Trillium Therapeutics Inc. Cd47 blockade therapy
CA3069523A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
NZ761568A (en) 2017-08-02 2022-11-25 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
JP7256580B2 (ja) 2017-08-18 2023-04-12 ウルトラヒューマン フォー リミティド 結合剤
CN109422811A (zh) * 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
AU2018351006B2 (en) * 2017-10-18 2024-08-29 Forty Seven, LLC Anti-CD47 agent-based ovarian cancer therapy
CA3080860A1 (en) 2017-11-01 2019-05-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 antigen-binding molecules
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same
US11771764B2 (en) 2017-11-06 2023-10-03 Pfizer Inc. CD47 blockade with radiation therapy
US11180552B2 (en) 2017-12-01 2021-11-23 Seagen Inc. CD47 antibodies and uses thereof for treating cancer
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
WO2019200462A1 (en) * 2018-04-16 2019-10-24 Adaerata, Limited Partnership Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers
CN108484770B (zh) * 2018-05-16 2020-11-13 武汉云克隆科技股份有限公司 重组大鼠抗小鼠cd4单克隆抗体，制备方法和应用
CN110538321B (zh) * 2018-05-29 2023-03-10 江苏恒瑞医药股份有限公司 一种cd47抗体药物组合物及其用途
WO2019241732A1 (en) * 2018-06-15 2019-12-19 Accurus Biosciences, Inc. Blocking antibodies against cd47 and methods of use thereof
CN110615841B (zh) * 2018-06-20 2022-01-04 瑞阳(苏州)生物科技有限公司 抗人cd47单克隆抗体及其应用
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
US20210324075A1 (en) * 2018-08-13 2021-10-21 Arch Oncology, Inc. Therapeutic cd47 antibodies
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US11987627B2 (en) 2018-08-31 2024-05-21 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-CD47 antibody and application thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113286613A (zh) * 2018-10-29 2021-08-20 Umc乌得勒支控股有限公司 IgA介导的通过中性粒细胞的CD47-SIRPα检查点抑制对异常细胞的杀伤
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
CN111253488A (zh) * 2018-12-03 2020-06-09 上海开拓者生物医药有限公司 Cd47抗体及其制备方法和应用
KR20210137477A (ko) 2019-03-06 2021-11-17 지앙수 헨그루이 메디슨 컴퍼니 리미티드 이중기능성 융합 단백질 및 그것의 제약학적 용도
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
CN114206912B (zh) 2019-06-07 2025-02-11 Alx肿瘤生物技术公司 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
CN113993899B (zh) * 2019-06-19 2024-03-29 乐普生物科技股份有限公司 抗cd47抗体及其应用
WO2020253785A1 (en) * 2019-06-19 2020-12-24 Lepu Biopharma Co., Ltd. Anti-cd47 antibodies and uses thereof
CN120775062A (zh) 2019-07-16 2025-10-14 吉利德科学公司 Hiv疫苗及其制备和使用方法
MX2022001305A (es) * 2019-07-30 2022-05-06 Akeso Biopharma Inc Anticuerpo de dominio proteínico p40 anti-humana y uso del mismo.
MX2022002613A (es) 2019-09-03 2022-06-02 Myeloid Therapeutics Inc Metodos y composiciones para la integracion del genoma.
AU2020342192A1 (en) * 2019-09-03 2022-04-21 Akeso Biopharma, Inc Anti-CD47 monoclonal antibody and use thereof
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
KR102866810B1 (ko) * 2019-10-25 2025-09-30 우시 바이올로직스 아일랜드 리미티드 신규한 항-cd47 항체 및 그 용도
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
EP4061420A1 (en) * 2019-11-20 2022-09-28 Abvision, Inc. Monoclonal antibodies that target human cd47 protein
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CN115244173A (zh) 2019-12-20 2022-10-25 英研生物(英国)有限公司 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途
AU2020412875A1 (en) 2019-12-24 2022-06-23 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
PH12022552122A1 (en) 2020-02-14 2024-01-29 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021190441A1 (zh) * 2020-03-23 2021-09-30 倍而达药业（苏州）有限公司 Cd47/人源化cd47抗体或其抗原结合片段、免疫活性片段及应用
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
BR112022019795A2 (pt) * 2020-04-02 2022-11-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd Polipeptídeo de ligação a antígeno que se liga a cd47 e uso deste
CN111635459B (zh) * 2020-06-27 2021-01-15 广东赛尔生物科技有限公司 抗cd47抗体及其在治疗癌症中的应用
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
EP4240356A1 (en) 2020-11-03 2023-09-13 RDiscovery, LLC Therapies for treatment of cancer and phagocytosis-deficiency related diseases
US20230399405A1 (en) * 2020-11-04 2023-12-14 The Trustees Of Dartmouth College Vista agonist for treatment/prevention of ischemic and/or reperfusion injury
GB2617474A (en) 2020-11-04 2023-10-11 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of use thereof
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
EP4262828A1 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
WO2022177392A1 (ko) * 2021-02-19 2022-08-25 (주)샤페론 Cd47에 대한 단일 도메인 항체 및 이의 용도
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
CN112979764B (zh) * 2021-03-26 2022-08-02 复旦大学附属中山医院 特异结合人cd47分子的多肽及其用途
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
GB2623653A (en) 2021-05-11 2024-04-24 Myeloid Therapeutics Inc Methods and compositions for genomic integration
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023159220A1 (en) * 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
ES2999273T3 (en) 2022-03-17 2025-02-25 Gilead Sciences Inc Ikaros zinc finger family degraders and uses thereof
JP2025509662A (ja) 2022-03-24 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
KR20250004824A (ko) 2022-04-21 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Kras g12d 조절 화합물
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
EP4554628A1 (en) 2022-07-12 2025-05-21 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
US20250100998A1 (en) 2023-07-26 2025-03-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN120648654A (zh) * 2024-03-13 2025-09-16 深圳太力生物技术有限责任公司 重组细胞的制备方法、重组细胞及其应用
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256654B1 (en) 1986-07-07 1996-09-18 Centocor, Inc. Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen
DE69839492D1 (de) 1997-09-11 2008-06-26 Chugai Pharmaceutical Co Ltd Monoklonale antikörper zur apoptosis-induzierung
US7531643B2 (en) 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
DE19813759C1 (de) 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
EP1167388A4 (en) 1999-03-10 2002-05-29 Chugai Pharmaceutical Co Ltd APOPTOSE INDUCING SINGLE STRING FV
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
CN1335887A (zh) * 1999-06-21 2002-02-13 印坎药物股份有限公司 血管抑制素∶一种Cys－Ser－Val－Thr－Cys－Gly特异性肿瘤细胞粘附受体
US20010041670A1 (en) * 1999-12-06 2001-11-15 Ronit Simantov Thrombospondin-binding region of histidine-rich glycoprotein and method of use
EP1519735A4 (en) 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
EP1693385A4 (en) 2003-11-11 2009-11-04 Chugai Pharmaceutical Co Ltd ANTI-CD47 ANTIBODIES HUMANIZED
WO2006031653A2 (en) 2004-09-10 2006-03-23 Wyeth Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
JP2007008895A (ja) 2005-07-04 2007-01-18 Chugai Pharmaceut Co Ltd 抗ｃｄ４７抗体とインテグリンリガンドとの併用
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
SG170091A1 (en) 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
WO2008043072A2 (en) 2006-10-05 2008-04-10 Biogen Idec Inc. Cd80 antagonists for treating neoplastic disorders
US8236313B2 (en) 2006-10-06 2012-08-07 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
AU2014201010B2 (en) 2008-01-15 2016-03-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
HUE050958T2 (hu) 2008-01-15 2021-01-28 Univ Leland Stanford Junior Akut mieloid leukémia õssejtek markerei
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
EP2340034B2 (en) 2008-08-07 2019-02-13 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Radioprotectants targeting thrombospondin-1 and cd47
EP4134095A1 (en) 2009-09-15 2023-02-15 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
CN102812041A (zh) 2010-01-21 2012-12-05 英穆尔诺基公司 治疗卵巢癌的组合物及方法
HUE060541T2 (hu) * 2010-05-14 2023-03-28 Univ Leland Stanford Junior Humanizált és kiméra monoklonális CD47 elleni ellenanyagok
WO2012047427A2 (en) 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US20140271683A1 (en) 2010-12-21 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
SMT201900453T1 (it) 2012-02-06 2019-11-13 Inhibrx Inc Anticorpi anti cd47 e relativi metodi d'uso
KR20150023811A (ko) 2012-06-21 2015-03-05 컴퓨젠 엘티디. 암의 치료를 위한 lsr 항체 및 그의 용도
DK2925782T3 (da) 2012-12-03 2020-04-06 Novimmune Sa Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
US9221908B2 (en) * 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
JP6572131B2 (ja) 2012-12-12 2019-09-04 バスキュロックス インコーポレイテッド 治療用ｃｄ４７抗体
KR102276974B1 (ko) 2013-02-06 2021-07-13 인히브릭스, 인크. 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
CN112245586A (zh) 2013-03-15 2021-01-22 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
CN103665165B (zh) 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
CN105263959A (zh) 2013-12-31 2016-01-20 财团法人生物技术开发中心 抗vegf抗体及其用途
JP6885606B2 (ja) 2015-09-18 2021-06-16 アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. 治療用ｃｄ４７抗体
US10946042B2 (en) 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
US20190309066A1 (en) 2017-03-22 2019-10-10 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
CA3057139A1 (en) 2017-03-22 2018-09-27 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47;DAVID D ROBERTS等;《MATRIX BIOLOGY》;20111210;第31卷(第3期);第162-169页 *
The Mechanism of CD47-Dependent Killing of T Cells: Heterotrimeric Gi-Dependent Inhibition of Protein Kinase A;P. P. MANNA等;《THE JOURNAL OF IMMUNOLOGY》;20030401;第170卷(第7期);第3544-3553页 *
Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1 /CD47 signaling;ISENBERG JS等;《SURGERY》;20081101;第144卷(第5期);第752-761页 *

Also Published As

Publication number Publication date
WO2015191861A1 (en) 2015-12-17
JP2016501892A (ja) 2016-01-21
AU2013359167B2 (en) 2018-08-23
ES2786083T3 (es) 2020-10-08
CN105102479A (zh) 2015-11-25
US20140363442A1 (en) 2014-12-11
PH12015501318A1 (en) 2015-08-24
US10676524B2 (en) 2020-06-09
EP2931751B1 (en) 2020-02-05
MX2015007446A (es) 2015-12-07
SG11201504469XA (en) 2015-07-30
HK1216647A1 (zh) 2016-11-25
US10669336B2 (en) 2020-06-02
US20150274826A1 (en) 2015-10-01
WO2014093678A3 (en) 2014-11-27
EP2931751A4 (en) 2016-07-13
US20180057592A1 (en) 2018-03-01
JP6572131B2 (ja) 2019-09-04
RU2015122228A (ru) 2017-01-19
IL239339A0 (en) 2015-07-30
KR20150093770A (ko) 2015-08-18
US20180051081A1 (en) 2018-02-22
NZ708445A (en) 2020-10-30
AU2013359167A1 (en) 2015-06-11
CA2894439A1 (en) 2014-06-19
BR112015013431A2 (pt) 2017-11-14
WO2014093678A2 (en) 2014-06-19
EP2931751A2 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
CN105102479B (zh) 治疗性cd47抗体
US11292834B2 (en) Therapeutic CD47 antibodies
JP6885606B2 (ja) 治療用ｃｄ４７抗体
AU2012266487B2 (en) Therapeutic antibodies
KR102166083B1 (ko) 브라디키닌 b1 수용체 리간드에 대한 항체
US11053318B2 (en) Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
EP3992211A1 (en) Anti-cea antibody and application thereof
JP2021532140A (ja) Ｃｄ３３及びｃｄ３に結合する二重特異性抗体コンストラクトの長期投与
NZ708445B2 (en) Therapeutic cd47 antibodies
RU2822550C9 (ru) Антитело против клаудина 18.2 и его применение
MX2013013911A (es) Anticuerpos terapeuticos.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190628

CF01 Termination of patent right due to non-payment of annual fee